Arrowhead partners two programs with Amgen

20 Dec 2022

Arrowhead Pharmaceuticals Inc. is partnering two of its RNA interference (RNAi) cardiovascular disease therapies with Amgen Inc.

Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email [email protected]

Related Companies

Arrowhead partners two programs with Amgen

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice